Incidence Of Hepatitis In Intensive Care Unit

Incidence Of Hepatitis And Its Effect On Prognosis In Patients Who Follow In Intensive Care Unit

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03456037

Enrollment

500

Registered

2018-03-07

Start date

2018-04-01

Completion date

2019-07-01

Last updated

2018-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intensive Care Unit

Keywords

HBsAg, Anti-HCV,, seropositivity

Brief summary

The aim is to investigate incidence of HBsAg, anti-HCV in serum samples and evaluation of biomarkers taken from patients who were followed the intensive care unit of Sakarya University Training and Research Hospital and The intensive care unit attracts attention by making health workers more susceptible to the risk of hepatitis.

Detailed description

This retrospective study included 536 cases who were followed with various diagnoses in intensive care units between 1 Ocak 2015 ile 1 Ocak 2016, covering the six months period, retrospectively. Sakarya University's Faculty of Medicine Review Board (71522473/050.01.04/113) approved the study after approval of the research ethics committee (. Medical record forms and electronic medical record system of the hospital were used in the analysis of medical data with regard to age, sex, HBsAg, anti-HCV, AST, ALT, bilirubin, creatinine levels.

Interventions

OTHERhepatitis viruses

There are 5 main hepatitis viruses, referred to as types A, B, C, D and E. These 5 types are of greatest concern because of the burden of illness and death they cause and the potential for outbreaks and epidemic spread. In particular, types B and C lead to chronic disease in hundreds of millions of people and, together, are the most common cause of liver cirrhosis and cancer.The aim is to investigate incidence of HBsAg, anti-HCV in serum samples and evaluation of biomarkers taken from patients who were followed the intensive care unit of Sakarya University Training and Research Hospital.

Study design

Observational model

OTHER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 120 Years

Healthy volunteers

Inclusion criteria

All patients who were followed in the intensive care unit

Exclusion criteria

None

Design outcomes

Primary

Measure	Time frame	Description
HBsAg	1 month	HBsAg is the serologic hallmark of HBV infection and is the first marker to appear after acute infection.

Secondary

Measure	Time frame	Description
anti-HCV	1mounth	Anti-HCV antibody tests look for antibodies to HCV in the blood, indicating an HCV infection has occurred.

Countries

Turkey (Türkiye)

Contacts

Primary ContactHavva Sayhan,, Assis Prof

hsayhan@gmail.com+905056621021

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026